{"id":"64cu-dota-ae105","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T17:44:51.401136","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"64Cu-DOTA-AE105 is a radioligand that targets somatostatin receptors, which are overexpressed in certain types of tumors.","oneSentence":"Somatostatin receptor targeting","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:27:24.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors"}]},"_fixedFields":["pubmed(6)"],"trialDetails":[{"nctId":"NCT06474806","phase":"PHASE2","title":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","status":"RECRUITING","sponsor":"Curasight","startDate":"2024-06-01","conditions":"Prostate Cancer","enrollment":168},{"nctId":"NCT02139371","phase":"EARLY_PHASE1","title":"Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-05","conditions":"Breast Cancer, Prostate Cancer, Urinary Bladder Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"recentPublications":[{"date":"2023 Dec","pmid":"37749438","title":"Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [(64)Cu]Cu-DOTA-AE105 uPAR-PET/CT in Patient-Derived Xenograft Models of Oral Squamous Cell Carcinoma.","journal":"Molecular imaging and biology"},{"date":"2017 Feb 28","pmid":"28039488","title":"uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.","journal":"Oncotarget"},{"date":"2014 Mar","pmid":"24533988","title":"Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.","journal":"Nuclear medicine and biology"},{"date":"2004","pmid":"22934319","title":"(64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-Asp-cyclohexylalanine-Phe-d-Ser-d-Arg-Tyr-Leu-Trp-Ser-NH(2) (AE105-NH(2)).","journal":""},{"date":"2012 Jan","pmid":"22213823","title":"Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"64Cu-DOTA-AE105","genericName":"64Cu-DOTA-AE105","companyName":"Curasight","companyId":"curasight","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatostatin receptor targeting Used for Neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}